Showing results (281-290 of 410) with videos related to
Sort By:
Pageof 41
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2024
Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047Hussein A Tawbi, F Stephen Hodi, Evan J Lipson, et al.Cell|September 9, 2017
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 ImmunotherapyAntoni Ribas, Reinhard Dummer, Igor Puzanov, et al.Kidney International|June 11, 2016
Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitorsFrank B Cortazar, Kristen A Marrone, Megan L Troxell, et al.Clinical Epigenetics|July 30, 2015
Targeted next-generation sequencing reveals high frequency of mutations in epigenetic regulators across treatment-naïve patient melanomasJonathan J Lee, Lynette M Sholl, Neal I Lindeman, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2017
Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced MelanomaMario Sznol, Pier Francesco Ferrucci, David Hogg, et al.Nature Communications|August 31, 2016
Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinomaJeffrey J Wallin, Johanna C Bendell, Roel Funke, et al.Journal for Immunotherapy of Cancer|May 4, 2023
Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trialJason A Chesney, Igor Puzanov, Frances A Collichio, et al.Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|August 27, 2022
Patient-reported tolerability of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III-IV melanoma in phase III trial E1609Laurie E McLouth, Yue Zheng, Stephanie Smith, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2003
Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinomaRavi Salgia, Thomas Lynch, Arthur Skarin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2016
Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With PembrolizumabF Stephen Hodi, Wen-Jen Hwu, Richard Kefford, et al.Pageof 41